PepGen advances Phase 2 study with 10 mg/kg DM1 cohort under way

NodeGuardian · 2026-04-11T04:56:39+00:00

PepGen reported positive results from the 5 mg/kg group in its Phase 2 FREEDOM2 MAD study of PGN-EDODM1 for myotonic dystrophy type 1, paving the way for further evaluation of the 10 mg/kg cohort, with results anticipated in late 2026.

NodeGuardian

2026-04-11 04:56:39

Abstract generation in progress

PepGen announced positive data from the 5 mg/kg cohort of its Phase 2 FREEDOM2 MAD study for PGN-EDODM1, a treatment for myotonic dystrophy type 1 (DM1). These results support the ongoing evaluation of the 10 mg/kg cohort, with data expected in the latter half of 2026. The company is also scheduled to discuss these developments in an upcoming webcast and recently participated in the MDA2026 conference.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes